RxDoctor Payments Data

Paul Dreyer, MD

Nephrology · Orlando, FLNPI 1194855528

Payments from drug & device makers

$40,499in general payments, 2019–2025

Across 314 payments — averaging $128.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$35K
  • Amgen$808
  • OPKO Pharmaceuticals, LLC$609
  • AstraZeneca$349
  • Otsuka America Pharmaceutical, Inc.$325
  • GSK$309
  • plus $3K from 34 others

What the payments were for

  • Speaking & faculty fees$31,88979%
  • Travel & lodging$2,0635%
  • Food & beverage$6,11015%
  • Education$4371%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,499 in reported general payments places this provider in the 85th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$391,202
Medicare patients
589
Services billed
4,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol86$139,856
ThiolaTiopronin12$122,107
KerendiaFinerenone37$50,429
Sevelamer Carbonate42$40,427
RayaldeeCalcifediol25$31,576
JardianceEmpagliflozin12$21,219
LokelmaSodium Zirconium Cyclosilicate16$16,000
OzempicSemaglutide12$15,357
MounjaroTirzepatide12$11,469
Potassium Citrate ErPotassium Citrate48$7,589
Febuxostat15$4,267
Nifedipine ErNifedipine56$1,507
ProsolParenteral Amino Acid 20% No.112$1,152
Eplerenone16$896
Hydralazine Hcl58$880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$349$155,856102 claims
BayerKerendia$34,745$50,42937 claims
OPKO Pharmaceuticals, LLCRayaldee$609$31,57625 claims
Boehringer IngelheimJardiance$71$21,21912 claims
Novo NordiskOzempic$60$15,35712 claims
Lilly USA, LLCMounjaro$18$11,46912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 756 nephrology providers in Florida.

Other nephrology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →